Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus pirfenidone versus nintedanib alone in idiopathic pulmonary fibrosis
2015-000640-42Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in idiopathic pulmonary fibrosis (IPF) comparing Ofev + pirfenidone with Ofev alone (2 arms). Primary endpoint: Percentage of patients with on-treatment gastrointestinal adverse events. Started Aug 2015; status: completed.
02
Drugs
nintedanibpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2015-000640-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000640-42.